- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05248191
FMT for Postop Crohn's Disease
Fecal Microbiota Transplant for Postoperative Crohn's Disease
People with Crohn's disease often need surgery. The gut bacteria of people with Crohn's is associated with Crohn's disease coming back after surgery. Fecal microbiota transplant (FMT) after surgery might be a way to prevent Crohn's disease from coming back after surgery.
This study aims to determine if fecal microbiota transplant (FMT) taken by capsules results in the same amount of good bacteria in the guts as FMT by colonoscopy in people with Crohn's disease who have had surgery.
Participants will be randomized to get FMT by capsules or colonoscopy. Colonoscopy with biopsies 8-weeks after the FMT will be used to assess the good bacteria in the gut.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Sharon Lopez
- Phone Number: 612-625-8999
- Email: skunkel@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able and willing to sign informed consent form
- Age 18 or older
- English speaking
- Established CD for at least 6-months based on typical clinical, endoscopic, and histopathic evidence.
- Prior ileocecal resection for CD
- Stable medications for 30 days
- Women of reproductive age: Agree to remain abstinent or use effective birth control
- Able and willing to comply with all study procedures
Exclusion Criteria:
- Antibiotic therapy within 15 days
- Probiotic therapy within 15 days
- Adenomatous polyps that have not been removed
- Anticipated antibiotic use over the study period
- Subtotal or total colectomy
- Current ostomy (ileostomy or colonoscopy)
- Anticipated surgical procedure over study period
- Pregnancy
- Severe food allergy
- Diagnosis of end stage liver disease or cirrhosis
- Absolute neutrophil count < 500 cell / uL
- Life expectancy < 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Capsule fecal microbiota material (cap-FMT)
Participants will receive colonoscopy at day 0 and week 8 and receive cap-FMT orally for five days post-colonoscopy.
Stool swabs and samples will be collected regularly.
|
Cap-FMT consists of Lyophilized FMT administered at 5 x 10^11 bacteria per capsule daily for five days, for a total dose of 2.5 x 10^12 bacteria.
|
Active Comparator: Colonoscopic fecal microbiota material (colo-FMT) plus placebo
Participants will receive colonoscopy at day 0 and week 8 and receive a placebo orally for five days post-colonoscopy.
During the first colonoscopy, colo-FMT will be administered.
Stool swabs and samples will be collected regularly.
|
Colo-FMT consists of rehydrated Lyophilized FMT material administered as a single dose of 2.5 x 10^12 bacteria as liquid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Ileal-associated microbiota engraftment
Time Frame: 8 weeks
|
Microbiota community of the ileum as sampled by ileal biopsies from colonoscopy.
We will use SourceTracker, a Bayesian community-wide software, to assess composition and donor similarity.
|
8 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Byron Vaughn, MD, MS, University of Minnesota Department of Medicine / Gastroenterology, Hepatology, Nutrition
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- GI-2022-30546
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crohn Disease
-
ProgenaBiomeRecruitingCrohn Disease | Crohn Colitis | Crohn's Ileocolitis | Crohn's Gastritis | Crohn's Jejunitis | Crohn's Duodenitis | Crohn's Esophagitis | Crohn's | Crohn Disease of Ileum | Crohn Ileitis | Crohn's Disease Relapse | Crohns Disease Aggravated | Crohn Disease in Remission | Crohn's Disease of PylorusUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...CelltrionRecruitingBowel Disease | Inflammatory Disease | Disease CrohnNetherlands
-
Chinese University of Hong KongTerminatedCrohn Disease | Perianal Crohn DiseaseHong Kong
-
SandozCompletedCrohn´s DiseaseAustria, Germany, Poland, Spain, Sweden
-
Dr. Falk Pharma GmbHCompleted
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Groupe Hospitalier Paris Saint JosephCompleted
-
Ferring PharmaceuticalsTerminatedCrohn´s DiseaseUnited Kingdom, United States, Germany, Belgium, Denmark, France, Sweden
-
Jinling Hospital, ChinaCompletedCrohn Disease in RemissionChina
-
Boehringer IngelheimTerminatedFibrostenotic Crohn´s DiseaseUnited States, Canada, Japan, Sweden
Clinical Trials on Capsule fecal microbiota material (cap-FMT)
-
M.D. Anderson Cancer CenterRecruitingPancreatic Ductal AdenocarcinomaUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
-
Fred Hutchinson Cancer CenterRecruitingAcute Graft Versus Host Disease | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Nanfang Hospital of Southern Medical UniversityUnknownSteroid-refractory Gastrointestinal Acute Graft Versus Host DiseaseChina
-
University of Wisconsin, MadisonWisconsin Partnership ProgramTerminatedAlzheimer DiseaseUnited States
-
Rima RachidCompletedPeanut AllergyUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingAllogeneic Hematopoietic Stem CellUnited States
-
St. Jude Children's Research HospitalNot yet recruiting
-
Massachusetts General HospitalCompleted
-
Children's Mercy Hospital Kansas CityUniversity of Pittsburgh; Stanford UniversityCompletedUlcerative Colitis (UC) | Inflammatory Bowel Diseases (IBD) | Crohn's Disease (CD)United States